Biotech News

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer

Nurix Therapeutics (NRIX)Nurix TherapeuticsCompany update

Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions BRISBANE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company

Related news

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ELVNEnliven Therapeutics2026-10-14 20:30 EST

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

FATEFate Therapeutics2026-10-12 11:00 EST

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

CGEMCullinan Therapeutics, Inc.2026-11-09 15:00 EST

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

GPCRStructure Therapeutics2026-11-04 12:30 EST

Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference

FATEFate Therapeutics2026-11-03 21:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

Nurix Therapeutics

Targeted Protein Degradation Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies. Bexobrutideg Bexobrutideg is an oral BTK degrader being advanced as a potential...

Recent company news

Stock data

Close
13.60 USD
Market cap
1.69B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States